BIOMAT Database Logo BIOMAT Database Logo

Serum protein binding of diphenylhydantoin in man. II. Interaction with sodium valproate in epileptic patients. 1979

G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
Effect of sodium valproate on plasma protein binding of diphenylhydantoin.
June 1977, Journal of neurology, neurosurgery, and psychiatry,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy.
January 1984, Therapeutic drug monitoring,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
Effect of single doses of sodium valproate on serum phenytoin levels and protein binding in epileptic patients.
January 1980, Clinical pharmacology and therapeutics,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
Intra-dose variation in plasma protein binding of sodium valproate in epileptic patients.
September 1982, British journal of clinical pharmacology,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
[Daily plasma fluctuations of diphenylhydantoin in patients treated with diphenylhydantoin and sodium valproate].
January 1981, Acta neurologica. Quaderni,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
[Daily fluctuations of plasma diphenylhydantoin in patients treated with diphenylhydantoin and sodium valproate].
February 1981, Acta neurologica,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
Disposition of sodium valproate in epileptic patients.
June 1978, British journal of clinical pharmacology,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
[Serum diphenylhydantoin in epileptic patients (preliminary report)].
January 1977, Neurologia i neurochirurgia polska,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients.
June 1997, Seizure,
G Gatti, and S Lecchini, and G M Frigo, and D Visintini, and S Calzetti, and M Lombardi, and G Cattaino
Plasma protein binding of diphenylhydantoin in man.
January 1971, Acta pharmacologica et toxicologica,
Copied contents to your clipboard!